Halliburton (HAL) Management Expects Tough 2016 - Oppenheimer Cuts PT to $40

KLR Group Upgrades Halliburton (HAL) to Buy

January 28, 2016 6:04 AM EST

KLR Group upgraded Halliburton (NYSE: HAL) from Hold to Buy with a price target of $44.00.

Analyst Darren Gacicia commented, "We are upgrading HAL to BUY for the following four reasons: 1) Large cap equity offers liquidity. 2) High North American exposure, which... More

UBS Remains Positive on Halliburton (HAL) With or Without BHI Merger - Reiterates Buy

January 26, 2016 8:54 AM EST

UBS maintained a Buy rating on Halliburton (NYSE: HAL), and cut the price target to $45.00 (from $48.00), following the company's 4Q earnings report. HAL Reported 4Q EPS of $0.31 vs. consensus of $0.24. On the much discussed merger with BHI, UBS remains constructive on HAL with or without the merger taking place. If the merger does not go through the $3.5 bil payout would equate to... More

HSBC Downgrades Halliburton (HAL) to Hold

January 26, 2016 7:13 AM EST

HSBC downgraded Halliburton (NYSE: HAL) from Buy to Hold.

For an analyst ratings summary and ratings history on Halliburton click here. For more ratings news on Halliburton click here.

Shares of Halliburton closed at $29.28 yesterday.

... More

Pre-Open Stock Movers 01/25: (AFMD) (GRUB) (SUNE) (TYC) Higher; (OMED) (NVAX) (TWTR) Lower (more...)

January 25, 2016 9:32 AM EST

OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) 43.7% LOWER; The DSMB informed OncoMed of several findings regarding futility of the trial, notably: A statistically significant worsening of response rate and progression-free survival (PFS) in the treatment arm in the overall intent-to-treat population, as well as a negative trend in each Notch biomarker subgroup; A strong trend to lack of benefit in the treatment arm for overall survival (OS), regardless of Notch biomarker levels, suggesting a low probability of achieving a statistically significant OS benefit based on analyses reviewed by the... More

Halliburton (HAL) Tops Q4 EPS by 7c

January 25, 2016 6:50 AM EST

Halliburton (NYSE: HAL) reported Q4 EPS of $0.31, $0.07 better than the analyst estimate of $0.24. Revenue for the quarter came in at $5.08 billion versus the consensus estimate of $5.11 billion.

We are pleased with our fourth quarter and full-year results in this challenging environment, as once again we outperformed our peer group in North America and international revenue, both sequentially and on a full-year basis, said Jeff Miller, President.

Total company annual revenue of $23.6 billion declined 28% year-over-year, outperforming a 35% decline in both the average worldwide rig count and global drilling and completions spend.

Our international business was... More

Investors look to Fed, earnings for direction next week

January 22, 2016 3:31 PM EST

By Chuck Mikolajczak

NEW YORK (Reuters) - Investors hoping equities can sustain their recent bounce next week will carefully watch the U.S. Federal Reserve's mid-week policy meeting for signs the central bank may slow the path of interest rate hikes.

The S&P 500 has already fallen as much as 9 percent this year, with stocks battered by concerns over China's slowing economy, plunging oil prices and Fed Vice Chairman Stanley Fischer's comments that he expected about four rate hikes this year.

But investors expect the Fed may soften its tone on interest rates when it... More

Trading Radar for 1/25: McDonald's (MCD), Halliburton (HAL), Kimberly-Clark (KMB), Rambus (RMBS) Report

January 22, 2016 2:35 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

Bank Of Hawaii Corp. (NYSE: BOH) - consensus EPS $0.93
Bank Of Marin Bancorp (Nasdaq: BMRC) - consensus EPS $0.78
D. R. Horton (NYSE:... More